Drugs / SYS6006
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05354063 | Jun → Sep 2022 | COVID-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05354089 | Apr → Jul 2022 | Orthocoronavirinae infectious disease | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07622225 | May 2026 → Dec 2028 expected | neoplasm | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05439824 | Jun 2022 → Jan 2023 | COVID-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05855408 | May 2023 → May 2024 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05492643 | Aug 2022 → Feb 2023 | COVID-19 | Zhongnan Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05354063 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 mRNA Vaccine (SYS6006)” NCT05354063 ↗ |
| Route | Intramuscular | “20 μg dose of SYS6006 vaccine IM on day 0 and day 21.” NCT05354063 ↗ |